ArticleNanotechnology2010
Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.
Article in Nanotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Nanoparticle technologies for liver targeting and their applications in liver diseases.Frontiers in bioengineering and biotechnology · 2025Review
- Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2022Review
- Microwave-Assisted Synchronous Nanogold Synthesis Reinforced by Kenaf Seed and Decoding Their Biocompatibility and Anticancer Activity.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nitric oxide releasing halloysite nanotubes for biomedical applications.Journal of colloid and interface science · 2021Article
- Nanotechnology and its use in imaging and drug delivery (Review).Biomedical reports · 2021Review
- Biosynthesis of Silver Nanoparticles by Marine ActinobacteriumFrontiers in microbiology · 2021Article
- Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis.Nanomaterials (Basel, Switzerland) · 2020Review
- Size and Shape-Dependent Antimicrobial Activities of Silver and Gold Nanoparticles: A Model Study as Potential Fungicides.Molecules (Basel, Switzerland) · 2020Article
- P311, Friend, or Foe of Tissue Fibrosis?Frontiers in pharmacology · 2018Review
- Nanomedicine applied to cardiovascular diseases: latest developments.Therapeutic advances in cardiovascular disease · 2017Review
- Nitric oxide in liver diseases.Trends in pharmacological sciences · 2015Review
- Silver nanoparticles synthesis mediated by new isolates of Bacillus spp., nanoparticle characterization and their activity against Bean Yellow Mosaic Virus and human pathogens.Frontiers in microbiology · 2015Article
- Nanotechnology applications for the therapy of liver fibrosis.World journal of gastroenterology · 2014Review
- Nanotoxicity comparison of four amphiphilic polymeric micelles with similar hydrophilic or hydrophobic structure.Particle and fibre toxicology · 2013Article
- Current concepts on the role of nitric oxide in portal hypertension.World journal of gastroenterology · 2013Review
- Nanocarriers for nitric oxide delivery.Journal of drug delivery · 2011Article
- Cytotoxicity of naphthoquinones and their capacity to generate reactive oxygen species is quenched when conjugated with gold nanoparticles.International journal of nanomedicine · 2011Article
- Nitric oxide generating/releasing materials.Future science OAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.